# Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Type 2 Diabetic Human Subjects

> **NCT00937326** · PHASE2 · COMPLETED · sponsor: **Sirtris, a GSK Company** · enrollment: 227 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** SRT2104
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00937326
- **Lead sponsor:** Sirtris, a GSK Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08-19
- **Primary completion:** 2010-09-18
- **Final completion:** 2010-09-18
- **Target enrollment:** 227 (ACTUAL)
- **Last updated:** 2018-07-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00937326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00937326, "Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Type 2 Diabetic Human Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00937326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*